A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Clinical trial NCT01636947 · COMPLETED

Trial details

NCT number: NCT01636947
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Nausea Vomiting

Start date: 2012-12-12
Primary completion: 2014-08-04
Enrollment: 494

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.